By the Top Tier Newswire AI Desk · August 21, 2026 at 10:21 AM ET · reviewed against 6 wire stories
BIONTECH SE ADR (BNTX) is up +6.65% in the latest session. Our newswire has captured 6 stories on BNTX across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
BNTX stock rose 6.65% to $118.26 on Thursday, driven by renewed optimism in the mRNA cancer vaccine space following positive data from Moderna and Merck. The broader biotech sector saw a rally after the Phase 3 success of the personalized cancer vaccine combination, which lifted related names including BioNTech. The stock opened at $110.95 and climbed steadily throughout the session, reaching a high of $118.69 before closing near that level.
What Happened
The recent biotech rally began when Moderna and Merck announced positive late-stage results for their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients. This breakthrough triggered a broad sector move, with Moderna surging 177% on Wednesday and Merck rising 13%. The momentum extended to BioNTech, which saw its shares climb as investors anticipated similar progress in its oncology pipeline. BioNTech is also preparing to present new data from its lung cancer treatment program at the 2026 World Conference on Lung Cancer, further supporting its position as a key player in the field.
What The Data Shows
Intraday volume was 0.6 million shares, which is 0.5 times the 3-month average, suggesting moderate participation. The stock closed near its session high, indicating strong buying pressure. On the 52-week tape, BNTX printed 44 fresh 52-week highs and one 52-week low on the same day, showing it is among the most active and volatile stocks. Despite the rally, the company remains unprofitable with a TTM net margin of -63.6% and a beta of 1.28, reflecting its high volatility relative to the market.
What To Watch
BioNTech will present new data from its lung cancer pipeline at the IASLC 2026 World Conference on Lung Cancer in September. Investors should monitor the company’s upcoming presentations for further validation of its oncology strategy and the potential for additional partnerships or clinical milestones.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BNTX · Aug 21 session (5-min) · +5.51% vs prior close · updated 8:51 PM ETAI sentiment, last 36h · averaged over 6 stories · 64/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
23d agoStocktwits NewsBULLISH 73Product/PR
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology
Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.
23d agoStocktwits NewsBULLISH 63Product/PR
ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back
The rally around MRNA names began on Wednesday after Merck and Moderna reported positive late-stage results for their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.
23d agoYahoo TopBEARISH 34Earnings
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
Shares of Moderna (NASDAQ:MRNA) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of Wednesday’s historic 177% rally. The reversal follows a Phase 3 win for Moderna’s personalized cancer vaccine, a result that repriced Moderna stock so violently in one session that a retrace looked close to inevitable. BioNTech (NASDAQ:BNTX) ... Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
24d agoMarketChameleonBULLISH 73Product/PR
BioNTech Showcases Pioneering Lung Cancer Pipeline and Unveils First-Ever Data for Novel Combination Therapy at WCLC 2026
August 20, 2026
BioNTech spotlights its expanding late-stage lung cancer treatment strategy, including the world’s first data for a unique immunotherapy/ADC combination and advances in chemotherapy-free regimens, reinforcing its position as a leader in next-generation oncology therapies.
24d agoStockTitanBULLISH 67Product/PR
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
The program includes five ongoing Phase 3 trials and two novel-novel combinations; WCLC presentations run Sept. 12-15, including updated survival data.
24d agoStocktwits NewsBULLISH 73Product/PR
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →